Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

Somatropin Treatment to Final Height in Turner Syndrome

Phase 3

Completed

Conditions: Turner Syndrome

Interventions: Drug: Ethinyl estradiol
Drug: Somatropin
Drug: Medroxyprogesterone acetate

First Posted Date: 2005-09-19

Last Posted Date: 2010-01-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 154

Registration Number: NCT00191113

Locations: 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 am - 5 pm Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sherbrooke, Quebec, Canada

An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD).

Phase 3

Completed

Conditions: Attention Deficit Hyperactivity Disorder
Oppositional Defiant Disorder

Interventions: Drug: atomoxetine 0.5 mg/kg/day
Drug: atomoxetine 1.2 mg/kg/day
Drug: placebo
Drug: atomoxetine 1.2-1.4 mg/kg/day

First Posted Date: 2005-09-19

Last Posted Date: 2010-01-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 139

Registration Number: NCT00192023

Locations: 🇮🇹
For additional Information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Cagliari, Italy
🇮🇹
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Venezia, Italy

A Phase III Trial For Patients With Metastatic Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer
Breast Neoplasms
Cancer of the Breast

Interventions: Drug: docetaxel
Drug: gemcitabine
Drug: capecitabine

First Posted Date: 2005-09-19

Last Posted Date: 2009-12-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 475

Registration Number: NCT00191152

Locations: 🇲🇽
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Michoacan, Mexico
🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician., Taipei, Taiwan
🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph, Tao-Yuan, Taiwan

and more 1 locations

To Investigate Efficacy and Safety of Pemetrexed as Second or Third Line Therapy in Patients With Non-small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Pemetrexed 500 mg/m2
Drug: Pemetrexed 1000 mg/m2

First Posted Date: 2005-09-19

Last Posted Date: 2009-12-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 226

Registration Number: NCT00191191

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Tokyo, Japan

A Trial for Patients With Advanced/Recurrent Cervical Cancer

Phase 2

Completed

Conditions: Cervical Intraepithelial Neoplasia
Uterine Neoplasms
Genital Neoplasms, Female

Interventions: Drug: Pemetrexed

First Posted Date: 2005-09-19

Last Posted Date: 2009-11-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 29

Registration Number: NCT00190983

Locations: 🇺🇸
Gynecologic Oncology Group 215-854-0770, Philadelphia, Pennsylvania, United States

A Study of Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Gemcitabine
Drug: Carboplatin
Drug: Herceptin

First Posted Date: 2005-09-19

Last Posted Date: 2009-11-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 150

Registration Number: NCT00191451

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States

A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: pemetrexed
Drug: cyclophosphamide

First Posted Date: 2005-09-19

Last Posted Date: 2009-11-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 103

Registration Number: NCT00190671

Locations: 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph, Saint Petersburg, Russian Federation

Combination Chemotherapy for Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Gemcitabine
Drug: cisplatin

First Posted Date: 2005-09-19

Last Posted Date: 2009-11-11

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 70

Registration Number: NCT00191815

Locations: 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9AM to 5PM Eastern time (UTC/ GMT - 5hours, EST), or speak with your personal physician, Moscow, Russian Federation

Instillation of Gemcitabine in Patients With Superficial Bladder Cancer

Phase 3

Terminated

Conditions: Bladder Neoplasms

Interventions: Drug: Gemcitabine
Drug: Placebo

First Posted Date: 2005-09-19

Last Posted Date: 2009-10-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 355

Registration Number: NCT00191477

Locations: 🇩🇪
For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559,1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physici, Reinfeld, Germany

A Study of Pemetrexed in the Treatment of Patients With Advanced Metastatic Cancer of the Liver

Phase 2

Completed

Conditions: Liver Cancer

First Posted Date: 2005-09-19

Last Posted Date: 2007-11-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 41

Registration Number: NCT00191412

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Denver, Colorado, United States

Home Terms & Conditions Privacy Policy